<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:3111307f-e892-43ee-ae27-a69a7927a801,g:ae7bbd0c-caca-4b5d-ac0b-1572fb9b7ca7,d:0a87d15755fd40faac55a3093d8b7d51--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>kin-20210205</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iafcc100a87af4b6ba33648dda8e56753_D20200511-20200511" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV80L2ZyYWc6ZDAxNzIwNTRhZTc5NGFlM2JmODE1MjczZDE5YjljNTEvdGFibGU6NjU5ZjgyOWUxODJkNGNkN2FkODdhNGU5MGU5MDI1MzQvdGFibGVyYW5nZTo2NTlmODI5ZTE4MmQ0Y2Q3YWQ4N2E0ZTkwZTkwMjUzNF8wLTEtMS0xLTA_99963bb1-f467-4eb6-9429-c1b216aff29f">0001561743</ix:nonNumeric><ix:nonNumeric contextRef="iafcc100a87af4b6ba33648dda8e56753_D20200511-20200511" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV80L2ZyYWc6ZDAxNzIwNTRhZTc5NGFlM2JmODE1MjczZDE5YjljNTEvdGFibGU6NjU5ZjgyOWUxODJkNGNkN2FkODdhNGU5MGU5MDI1MzQvdGFibGVyYW5nZTo2NTlmODI5ZTE4MmQ0Y2Q3YWQ4N2E0ZTkwZTkwMjUzNF8xLTEtMS0xLTA_bb886d12-d2c1-4b24-afeb-516e8ea4b845">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="kin-20210205.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iecce078d93af4a37b3379987c74b8600_D20210205-20210205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561743</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81e2ed71882c41b393f43b0d456bdd5b_D20210205-20210205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4c0861ff0f946539d7f98a7ec06677d_D20210205-20210205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561743</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafcc100a87af4b6ba33648dda8e56753_D20200511-20200511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001561743</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-11</xbrli:startDate><xbrli:endDate>2020-05-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i0a87d15755fd40faac55a3093d8b7d51_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="iecce078d93af4a37b3379987c74b8600_D20210205-20210205" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGV4dHJlZ2lvbjozYzQ5ZDQ0YWI0MmM0NmM3YWNhMWI2ODJmMmQzNjg3NV84MzY_e734bec8-2fdd-4b2a-aed9-0928e66c3973">8-K</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">the Securities Exchange Act of 1934 </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date of report (Date of earliest event reported): <ix:nonNumeric contextRef="iecce078d93af4a37b3379987c74b8600_D20210205-20210205" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGV4dHJlZ2lvbjozYzQ5ZDQ0YWI0MmM0NmM3YWNhMWI2ODJmMmQzNjg3NV84NDA_1caffd47-57ef-4415-afa5-85d9c3db5b37">February 5, 2021</ix:nonNumeric> </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iecce078d93af4a37b3379987c74b8600_D20210205-20210205" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGV4dHJlZ2lvbjozYzQ5ZDQ0YWI0MmM0NmM3YWNhMWI2ODJmMmQzNjg3NV84Mzc_3a3c7206-560e-4376-9693-c451cf5d681e">KINDRED BIOSCIENCES, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:32.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.851%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iecce078d93af4a37b3379987c74b8600_D20210205-20210205" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGFibGU6ZDdiYTdlMGI4ZjcyNGVhNDgwOTc1N2RkZTE0YjRjMDkvdGFibGVyYW5nZTpkN2JhN2UwYjhmNzI0ZWE0ODA5NzU3ZGRlMTRiNGMwOV8wLTAtMS0xLTA_83c0a491-7f98-45c5-9062-40aa97848c51">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iecce078d93af4a37b3379987c74b8600_D20210205-20210205" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGFibGU6ZDdiYTdlMGI4ZjcyNGVhNDgwOTc1N2RkZTE0YjRjMDkvdGFibGVyYW5nZTpkN2JhN2UwYjhmNzI0ZWE0ODA5NzU3ZGRlMTRiNGMwOV8wLTItMS0xLTA_2a0d811a-02c7-477e-8ab7-e4e2b65b7563">001-36225</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iecce078d93af4a37b3379987c74b8600_D20210205-20210205" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGFibGU6ZDdiYTdlMGI4ZjcyNGVhNDgwOTc1N2RkZTE0YjRjMDkvdGFibGVyYW5nZTpkN2JhN2UwYjhmNzI0ZWE0ODA5NzU3ZGRlMTRiNGMwOV8wLTQtMS0xLTA_9971dbff-c6cf-4dac-9f7a-42328177c977">46-1160142</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iecce078d93af4a37b3379987c74b8600_D20210205-20210205" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGV4dHJlZ2lvbjozYzQ5ZDQ0YWI0MmM0NmM3YWNhMWI2ODJmMmQzNjg3NV84NDE_7e584256-a5f9-4292-96da-4356ac899a32">1555 Bayshore Highway</ix:nonNumeric>, <ix:nonNumeric contextRef="iecce078d93af4a37b3379987c74b8600_D20210205-20210205" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGV4dHJlZ2lvbjozYzQ5ZDQ0YWI0MmM0NmM3YWNhMWI2ODJmMmQzNjg3NV84NDI_201c6ab8-15a8-4de1-982f-ed52f97002b1">Suite 200</ix:nonNumeric>, <ix:nonNumeric contextRef="iecce078d93af4a37b3379987c74b8600_D20210205-20210205" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGV4dHJlZ2lvbjozYzQ5ZDQ0YWI0MmM0NmM3YWNhMWI2ODJmMmQzNjg3NV84Mzg_5b389558-3fd8-4702-b114-682b59cbf3a8">Burlingame</ix:nonNumeric>, <ix:nonNumeric contextRef="iecce078d93af4a37b3379987c74b8600_D20210205-20210205" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGV4dHJlZ2lvbjozYzQ5ZDQ0YWI0MmM0NmM3YWNhMWI2ODJmMmQzNjg3NV84Mzk_dd07cfdb-c7d6-4a4f-888a-c45ad5361531">California</ix:nonNumeric> <ix:nonNumeric contextRef="iecce078d93af4a37b3379987c74b8600_D20210205-20210205" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGV4dHJlZ2lvbjozYzQ5ZDQ0YWI0MmM0NmM3YWNhMWI2ODJmMmQzNjg3NV84NDM_372a2694-bd79-4d93-8bd4-fcf8d283b6de">94010</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Address of principal executive offices) (Zip Code) </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="iecce078d93af4a37b3379987c74b8600_D20210205-20210205" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGV4dHJlZ2lvbjozYzQ5ZDQ0YWI0MmM0NmM3YWNhMWI2ODJmMmQzNjg3NV84NDQ_79ab1ea7-2435-465a-bdd6-ea81d311a528">650</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="iecce078d93af4a37b3379987c74b8600_D20210205-20210205" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGV4dHJlZ2lvbjozYzQ5ZDQ0YWI0MmM0NmM3YWNhMWI2ODJmMmQzNjg3NV84NDU_dbcc8e07-b024-483f-b784-231ac85e9595">701-7901</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report) </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:3.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iecce078d93af4a37b3379987c74b8600_D20210205-20210205" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGFibGU6ZTc1MDY3M2MzMTI5NDk4NjhkMGZkNjFiNmNkYjQ3NWYvdGFibGVyYW5nZTplNzUwNjczYzMxMjk0OTg2OGQwZmQ2MWI2Y2RiNDc1Zl8wLTAtMS0xLTA_e2cfaf90-36a7-479f-a146-28dc285ec14d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iecce078d93af4a37b3379987c74b8600_D20210205-20210205" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGFibGU6ZTc1MDY3M2MzMTI5NDk4NjhkMGZkNjFiNmNkYjQ3NWYvdGFibGVyYW5nZTplNzUwNjczYzMxMjk0OTg2OGQwZmQ2MWI2Y2RiNDc1Zl8xLTAtMS0xLTA_500823c4-5b67-4d14-af57-f8bc82b90c46">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iecce078d93af4a37b3379987c74b8600_D20210205-20210205" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGFibGU6ZTc1MDY3M2MzMTI5NDk4NjhkMGZkNjFiNmNkYjQ3NWYvdGFibGVyYW5nZTplNzUwNjczYzMxMjk0OTg2OGQwZmQ2MWI2Y2RiNDc1Zl8yLTAtMS0xLTA_78ca3a11-2d50-4d2c-bc9a-77dd844cb3c6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iecce078d93af4a37b3379987c74b8600_D20210205-20210205" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGFibGU6ZTc1MDY3M2MzMTI5NDk4NjhkMGZkNjFiNmNkYjQ3NWYvdGFibGVyYW5nZTplNzUwNjczYzMxMjk0OTg2OGQwZmQ2MWI2Y2RiNDc1Zl8zLTAtMS0xLTA_af06b65d-72c7-45c9-8592-38df69780c97">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:37.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i81e2ed71882c41b393f43b0d456bdd5b_D20210205-20210205" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGFibGU6YmM3MTIyODc1MmU4NGUyYWJlODhiNGRiNGIzZjlkZTAvdGFibGVyYW5nZTpiYzcxMjI4NzUyZTg0ZTJhYmU4OGI0ZGI0YjNmOWRlMF8xLTAtMS0xLTA_9b32b1d9-8bbb-4c07-a311-f9777d95ee97">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i81e2ed71882c41b393f43b0d456bdd5b_D20210205-20210205" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGFibGU6YmM3MTIyODc1MmU4NGUyYWJlODhiNGRiNGIzZjlkZTAvdGFibGVyYW5nZTpiYzcxMjI4NzUyZTg0ZTJhYmU4OGI0ZGI0YjNmOWRlMF8xLTItMS0xLTA_3cd15204-3784-4e5c-9deb-13fbee1a9e1b">KIN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i81e2ed71882c41b393f43b0d456bdd5b_D20210205-20210205" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGFibGU6YmM3MTIyODc1MmU4NGUyYWJlODhiNGRiNGIzZjlkZTAvdGFibGVyYW5nZTpiYzcxMjI4NzUyZTg0ZTJhYmU4OGI0ZGI0YjNmOWRlMF8xLTQtMS0xLTA_593a341e-b96a-4711-a7de-ac8feb260fe9">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia4c0861ff0f946539d7f98a7ec06677d_D20210205-20210205" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGFibGU6YmM3MTIyODc1MmU4NGUyYWJlODhiNGRiNGIzZjlkZTAvdGFibGVyYW5nZTpiYzcxMjI4NzUyZTg0ZTJhYmU4OGI0ZGI0YjNmOWRlMF8yLTAtMS0xLTA_edf20573-0586-4f09-b54d-10962c1cd6eb">Preferred Stock Purchase Rights</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia4c0861ff0f946539d7f98a7ec06677d_D20210205-20210205" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGFibGU6YmM3MTIyODc1MmU4NGUyYWJlODhiNGRiNGIzZjlkZTAvdGFibGVyYW5nZTpiYzcxMjI4NzUyZTg0ZTJhYmU4OGI0ZGI0YjNmOWRlMF8yLTItMS0xLTA_76b249e9-3caa-46db-aeda-a88a50e7902c">KIN</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia4c0861ff0f946539d7f98a7ec06677d_D20210205-20210205" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGFibGU6YmM3MTIyODc1MmU4NGUyYWJlODhiNGRiNGIzZjlkZTAvdGFibGVyYW5nZTpiYzcxMjI4NzUyZTg0ZTJhYmU4OGI0ZGI0YjNmOWRlMF8yLTQtMS0xLTA_3f259fb8-55e8-4918-8495-6fca5574aa8b">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:19.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.199%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iecce078d93af4a37b3379987c74b8600_D20210205-20210205" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjBhODdkMTU3NTVmZDQwZmFhYzU1YTMwOTNkOGI3ZDUxL3NlYzowYTg3ZDE1NzU1ZmQ0MGZhYWM1NWEzMDkzZDhiN2Q1MV8xL2ZyYWc6M2M0OWQ0NGFiNDJjNDZjN2FjYTFiNjgyZjJkMzY4NzUvdGFibGU6NDU4ZjUwYWNlYTRjNGI2OGFiZjYyYjQyOTcwN2RmOWUvdGFibGVyYW5nZTo0NThmNTBhY2VhNGM0YjY4YWJmNjJiNDI5NzA3ZGY5ZV8xLTUtMS0xLTA_748b87cd-dd28-4f6d-8cf3-dadee32719f2">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i0a87d15755fd40faac55a3093d8b7d51_7"></div><div style="-sec-extract:summary;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:103%">Item 5.02&#160;&#160;&#160;&#160;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">On February 5, 2021, the board of directors (the &#8220;Board&#8221;) of Kindred Biosciences, Inc. (&#8220;KindredBio&#8221;) appointed Nanxi Liu and Lyndon Lien, Ph.D., to serve as Class I directors of KindredBio, effective as of February 5, 2021, with each director having a term that expires at the 2023 annual meeting of stockholders. As a result of Ms. Liu and Dr. Lien's appointment, the authorized size of the Board was increased to eight members.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">There is no arrangement or understanding between Ms. Liu and any other person pursuant to which Ms. Liu was selected as a director. There is no arrangement or understanding between Dr. Lien and any other person pursuant to which Dr. Lien was selected as a director. There are no relationships between Ms. Liu and the Company or Dr. Lien and the Company that would require disclosure pursuant to Item 404(a) of Regulation S-K.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Each of Ms. Liu and Dr. Lien is an independent director in accordance with the listing requirements of The NASDAQ Stock Market. Ms. Liu and Dr. Lien's compensation will be consistent with the compensation of KindredBio&#8217;s other non-employee directors. Ms. Liu shall serve on the Board's Audit Committee, and Dr. Lien shall serve on the Board's Nominating and Corporate Governance Committee. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">In accordance with the previous announcement by Ernest Mario, Ph.D. of his intention to retire as a director upon the appointment of a replacement director, as reported on a Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2020, Dr. Mario retired from the Board on February 5, 2021. Dr. Mario will remain as an advisor to KindredBio for the remainder of 2021. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Lyndon Lien is Chief Executive Officer and co-founder of Qinotto, a biopharmaceutical company discovering and developing therapeutics for neurological diseases. Previously, he was Operating Partner at Pivotal bioVenture Partners, a life sciences venture capital firm. He was also Chief Executive Officer and co-founder of Balance Therapeutics, a rare cognition and sleep disorder biopharmaceutical company which he led from early preclinical development through Phase 2 clinical trials. Dr. Lien previously served in various strategy, business development, and operating roles at Elan, J&amp;J, and McKinsey &amp; Company. Dr. Lien received a PhD in Genetics and an AB from Harvard University, and an MBA from MIT Sloan School of Management.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Nanxi Liu is Chief Executive Officer and co-founder of Enplug, a digital display software company used by Fortune 500 companies, and was named one of Forbes 30 Under 30 and Fortune's 10 Most Promising Women Entrepreneurs. She also co-founded Nanoly Bioscience, a venture-backed biotech company that develops polymers that enable vaccines and other biologics to be stored without refrigeration. Ms. Liu serves on the board of directors of CarParts.com, on the Board of Advisors for Covington Capital Management, and on the California Department of Motor Vehicles&#8217; New Motor Vehicle Board. She received a BS in Business Administration and BA in Political Economy from UC Berkeley.</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:103%">Item 7.01&#160;&#160;&#160;&#160;Regulation FD Disclosure.</span></div><div style="padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A copy of the press release dated February 9, 2021 announcing the appointments of Ms. Liu and Dr. Lien is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The information in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Act of 1933, or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such a filing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:103%">Item 9.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:103%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:103%">Financial Statements and Exhibits.</span></div><div style="padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.686%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="pr_kindredbioboardappointm.htm">Press Release dated February 9, 2021, by Kindred Biosciences, Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">KINDRED BIOSCIENCES, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:   February 9, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Richard Chin         </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Richard Chin, M.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "kin-20210205.htm", "description": "8-K", "secsgml_size_bytes": 43366}]
{"company-data": {"conformed-name": "Kindred Biosciences, Inc.", "cik": "0001561743", "assigned-sic": "2834", "irs-number": "461160142", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-36225", "film-number": "21604081"}, "business-address": {"street1": "1555 BAYSHORE HIGHWAY, SUITE 200", "city": "BURLINGAME", "state": "CA", "zip": "94010", "phone": "650-701-7901"}, "mail-address": {"street1": "1555 BAYSHORE HIGHWAY, SUITE 200", "city": "BURLINGAME", "state": "CA", "zip": "94010"}}
kin-20210205
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
February 5, 2021
KINDRED BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-36225
46-1160142
(State or other jurisdiction of
incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
1555 Bayshore Highway
,
Suite 200
,
Burlingame
,
California
94010
(Address of principal executive offices) (Zip Code)
(
650
)
701-7901
(Registrant's telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.0001 par value
KIN
The NASDAQ Stock Market LLC
Preferred Stock Purchase Rights
KIN
The NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 5, 2021, the board of directors (the "Board") of Kindred Biosciences, Inc. ("KindredBio") appointed Nanxi Liu and Lyndon Lien, Ph.D., to serve as Class I directors of KindredBio, effective as of February 5, 2021, with each director having a term that expires at the 2023 annual meeting of stockholders. As a result of Ms. Liu and Dr. Lien's appointment, the authorized size of the Board was increased to eight members.
There is no arrangement or understanding between Ms. Liu and any other person pursuant to which Ms. Liu was selected as a director. There is no arrangement or understanding between Dr. Lien and any other person pursuant to which Dr. Lien was selected as a director. There are no relationships between Ms. Liu and the Company or Dr. Lien and the Company that would require disclosure pursuant to Item 404(a) of Regulation S-K.
Each of Ms. Liu and Dr. Lien is an independent director in accordance with the listing requirements of The NASDAQ Stock Market. Ms. Liu and Dr. Lien's compensation will be consistent with the compensation of KindredBio's other non-employee directors. Ms. Liu shall serve on the Board's Audit Committee, and Dr. Lien shall serve on the Board's Nominating and Corporate Governance Committee.
In accordance with the previous announcement by Ernest Mario, Ph.D. of his intention to retire as a director upon the appointment of a replacement director, as reported on a Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2020, Dr. Mario retired from the Board on February 5, 2021. Dr. Mario will remain as an advisor to KindredBio for the remainder of 2021.
Lyndon Lien is Chief Executive Officer and co-founder of Qinotto, a biopharmaceutical company discovering and developing therapeutics for neurological diseases. Previously, he was Operating Partner at Pivotal bioVenture Partners, a life sciences venture capital firm. He was also Chief Executive Officer and co-founder of Balance Therapeutics, a rare cognition and sleep disorder biopharmaceutical company which he led from early preclinical development through Phase 2 clinical trials. Dr. Lien previously served in various strategy, business development, and operating roles at Elan, J&J, and McKinsey & Company. Dr. Lien received a PhD in Genetics and an AB from Harvard University, and an MBA from MIT Sloan School of Management.
Nanxi Liu is Chief Executive Officer and co-founder of Enplug, a digital display software company used by Fortune 500 companies, and was named one of Forbes 30 Under 30 and Fortune's 10 Most Promising Women Entrepreneurs. She also co-founded Nanoly Bioscience, a venture-backed biotech company that develops polymers that enable vaccines and other biologics to be stored without refrigeration. Ms. Liu serves on the board of directors of CarParts.com, on the Board of Advisors for Covington Capital Management, and on the California Department of Motor Vehicles' New Motor Vehicle Board. She received a BS in Business Administration and BA in Political Economy from UC Berkeley.
Item 7.01    Regulation FD Disclosure.
A copy of the press release dated February 9, 2021 announcing the appointments of Ms. Liu and Dr. Lien is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Act of 1933, or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01
Financial Statements and Exhibits.
Exhibit No.
Description
99.1
Press Release dated February 9, 2021, by Kindred Biosciences, Inc.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
KINDRED BIOSCIENCES, INC.
Date:   February 9, 2021
By:
/s/ Richard Chin
Richard Chin, M.D.
Chief Executive Officer